Impact of Adjuvant Medical Therapies on Surgical Outcomes in
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Adjuvant medications including proton pump inhibitors (PPI), antibiotics (trimethoprim/sulfamethoxazole [TMP-SMX]), and inhaled corticosteroids (ICS) may be prescribed for patients with idiopathic subglottic stenosis (iSGS). But this study finds that there is no standard practice for prescribing adjuvant medications.

Investigators describe medication use with endoscopic dilation (ED) or endoscopic resection with medical treatment (ERMT) and evaluate the impact on outcomes.

An International, prospective, 3-year multicenter cohort study of 810 patients with untreated, newly diagnosed, or previously treated iSGS was carried out.

Post hoc secondary analysis of prospectively collected North American Airway Collaborative data on outcomes linked with adjuvant medication utilization. The primary outcome was time to recurrent operation, evaluated using Kaplan–Meier curves and Cox regression analysis. Secondary outcomes of change in peak expiratory flow (PEF) and clinical chronic obstructive pulmonary disease questionnaire (CCQ) score over 12?months were compared.

Sixty-one of 129 patients undergoing ED received PPI, and 10/143 patients undergoing ED received ICS. TMP-SMX was used by 87/115 patients undergoing EMRT.

- PPI use in the ED group did not affect time to recurrence or 12-month change in PEF (L/min) but was associated with a 12-month change in CCQ.

- ICS did not affect outcome measures. TMP-SMX use in ERMT did not affect time to recurrence, PEF at 12?months, or 12-month change in CCQ.

These data do not support that adjuvant medications prolong time to recurrence or increase PEF. Patients with iSGS and gastroesophageal reflux disease may experience some symptom benefits with PPI.

The Laryngoscope